نتایج جستجو برای: hiv 1 dna vaccine

تعداد نتایج: 3346593  

Journal: :Current HIV research 2008
Zuhu Huang Arthur Chou Jonathan Tanguay Siyuan Shen Innocent Mboudjeka Te-Hui Chou Shan Lu Shixia Wang

A good understanding about the structure and function of the envelope glycoprotein (Env) from primary human immunodeficiency virus-1 (HIV-1) isolates is important in facilitating the development of effective neutralizing antibody responses as a component of an effective HIV-1 vaccine. In the current study, the antigenicity of a panel of diverse HIV-1 primary Env from different clades of HIV-1 G...

2010
Hong Qin Pramod N. Nehete Hong He Bharti Nehete Stephanie Buchl Soung-chul Cha Jagannadha K. Sastry Larry W. Kwak

HIV vaccine candidates with improved immunogenicity and induction of mucosal T-cell immunity are needed. A prime-boost strategy using a novel HIV glycoprotein 120 DNA vaccine was employed to immunize rhesus macaques. The DNA vaccine encoded a chimeric gp120 protein in fusion with monocyte chemoattractant protein-3, which was hypothesized to improve the ability of antigen-presenting cells to cap...

2010
Gregory G. Simon Yongli Hu Asif M. Khan Jingshi Zhou Jerome Salmon Priya R. Chikhlikar Keun-Ok Jung Ernesto T. A. Marques J. Thomas August

This report describes the identification and bioinformatics analysis of HLA-DR4-restricted HIV-1 Gag epitope peptides, and the application of dendritic cell mediated immunization of DNA plasmid constructs. BALB/c (H-2d) and HLA-DR4 (DRA1*0101, DRB1*0401) transgenic mice were immunized with immature dendritic cells transfected by a recombinant DNA plasmid encoding the lysosome-associated membran...

2017
Miriam Rosás-Umbert Beatriz Mothe Marc Noguera-Julian Rocío Bellido Maria C Puertas Jorge Carrillo C Rodriguez Núria Perez-Alvarez Patricia Cobarsí Carmen E Gomez Mariano Esteban Jose Luis Jímenez Felipe García Julià Blanco Javier Martinez-Picado Roger Paredes Christian Brander

The most relevant endpoint in therapeutic HIV vaccination is the assessment of time to viral rebound or duration of sustained control of low-level viremia upon cART treatment cessation. Structured treatment interruptions (STI) are however not without risk to the patient and reliable predictors of viral rebound/control after therapeutic HIV-1 vaccination are urgently needed to ensure patient saf...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه تربیت مدرس - دانشکده پزشکی 1393

زمینه و هدف: تحویل مستقیم آنتی¬ژن به سلول های دندریتیک موجب تقویت پاسخ های ایمنی می شود و راهکاری مناسب در مبارزه علیه پاتوژن¬هایی نظیر hiv می¬یاشد. هدف این مطالعه بررسی پاسخ های ایمنی حاصل از تحویل مستقیم پروتئین نوترکیب چنداپی توپی tat/pol/gag/env ویروس 1-hiv در مرحله تزریق یادآور با کمک آنتی بادی منوکلونال علیه 205-dec موجود در سطح سلول های دندریتیک موش جهت تقویت پاسخ های ایمنی است. مواد ...

Journal: :Vaccine 2007
Barry S Peters Walter Jaoko Eftyhia Vardas George Panayotakopoulos Patricia Fast Claudia Schmidt Jill Gilmour Mampedi Bogoshi Gloria Omosa-Manyonyi Len Dally Linda Klavinskis Bashir Farah Tony Tarragona Pierre-Alexandre Bart Andrew Robinson Colleen Pieterse Wendy Stevens Richard Thomas Burc Barin Andrew J McMichael James A McIntyre Giuseppe Pantaleo Tomás Hanke Job Bwayo

BACKGROUND Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 clade A gag p24 and p17 fused to a string of 25 overlapping CD8+ T cell epitopes (HIVA). METHODS These studies compared intramuscular, subcutaneous, and intradermal MVA at d...

2013
Man Li Yuhong Jiang Chaoqun Xu Zhirong Zhang Xun Sun

BACKGROUND The heterologous deoxyribonucleic acid (DNA) prime-adenovirus (AdV) boost vaccination approach has been widely applied as a promising strategy against human immunodeficiency virus (HIV)-1. However, the problem of inefficient delivery and lack of specificity of DNA vaccine remains a major issue. In this paper, to improve the transfection of DNA vaccine and realize dendritic cell targe...

Journal: :Journal of virology 2016
Matthew R Costa Justin Pollara Regina Whitney Edwards Michael S Seaman Miroslaw K Gorny David C Montefiori Hua-Xin Liao Guido Ferrari Shan Lu Shixia Wang

HIV-1 is able to elicit broadly potent neutralizing antibodies in a very small subset of individuals only after several years of infection, and therefore, vaccines that elicit these types of antibodies have been difficult to design. The RV144 trial showed that moderate protection is possible and that this protection may correlate with antibody-dependent cellular cytotoxicity (ADCC) activity. Ou...

2015
Charlotta Nilsson Bo Hejdeman Karina Godoy-Ramirez Teghesti Tecleab Gabriella Scarlatti Andreas Bråve Patricia L. Earl Richard R. Stout Merlin L. Robb Robin J. Shattock Gunnel Biberfeld Eric Sandström Britta Wahren Javier R. Lama

BACKGROUND We compared safety and immunogenicity of intradermal (ID) vaccination with and without electroporation (EP) in a phase I randomized placebo-controlled trial of an HIV-DNA prime HIV-MVA boost vaccine in healthy Swedish volunteers. METHODS HIV-DNA plasmids encoding HIV-1 genes gp160 subtypes A, B and C; Rev B; Gag A and B and RTmut B were given ID at weeks 0, 6 and 12 in a dose of 0....

Journal: :Journal of virology 2005
Ying Lian Indresh Srivastava V Rául Gómez-Román Jan Zur Megede Yide Sun Elaine Kan Susan Hilt Susan Engelbrecht Sunee Himathongkham Paul A Luciw Gillis Otten Jeffrey B Ulmer John J Donnelly Dietmar Rabussay David Montefiori Estrelita Janse van Rensburg Susan W Barnett

Human immunodeficiency virus type 1 (HIV-1) subtype C infections are on the rise in Sub-Saharan Africa and Asia. Therefore, there is a need to develop an HIV vaccine capable of eliciting broadly reactive immune responses against members of this subtype. We show here that modified HIV envelope (env) DNA vaccines derived from the South African subtype C TV1 strain are able to prime for humoral re...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید